BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CTD Holdings, Inc. Formalizes International Sales of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Type C (NPC)


3/15/2010 11:03:39 AM

HIGH SPRINGS, FL--(Marketwire - March 15, 2010) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ). During 2009 the company successfully supplied Cyclo™ for the treatment of NPC to children in India, Lebanon, Spain, Brazil, and Japan. "We are monitoring the results of these interventions and continue to supply larger amounts of Cyclo™ to the requesting medical facilities as they implement the AddiandCassi protocol," stated CEO, Rick Strattan. He continued, "The Company expects significant growth in its international sales of the Cyclo™ product line in 2010."

Recently, the AddiandCassi Foundation (www.Addiandcassi.com) had their orphan drug application accepted by the US FDA for Trappsol® Cyclo™ to treat NPC.

NPC is one of at least 42 rare, fatal diseases which are classed as lysosomal storage diseases (LSD). The enormous medical interest generated by the ameliorative results as achieved in treating NPC has brought these other rare diseases into the limelight giving hope that they, too, can benefit from Cyclo™ use.

About CTD Holdings, Inc.

The company is the one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists coordinate the development of commercial products for use in many diverse industries that endeavor to put non water-soluble ingredients into water-based formulations for direct use or conversion into stable, easy to use powders.

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH is timely in the filing of its SEC mandated financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.


Contact:
Rick Strattan
386-454-0887



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES